{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:07:08Z","timestamp":1790089628114,"version":"4.0.1"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Stage at diagnosis, histologic grade, and molecular subtypes are established prognostic indicators for women with breast cancer (BC), but their impact on population-based survival estimates is poorly documented. This study assessed long-term BC survival trends according to these factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified women aged &amp;lt;75\u2009years diagnosed with stage I-IV invasive BC between 2004 and 2014 from the Friuli Venezia Giulia (north-eastern Italy) Cancer Registry (N\u2009=\u200910\u00a0467). Follow-up through 2023 was used to estimate overall and net survival (NS) according to combinations of prognostic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The highest 10-year NS (10-NS) was observed in women with stage I HR+\/HER2\u2212 subtype (98.8%), while it was 35.1% for stage III triple-negative (TN) subtype. Among women with stage IV BC, 10-NS was 18.9% for those HR\u2212\/HER2+, 11.5% for those HR+\/HER2+, 8.3% for HR+\/HER2\u2212, and 6.7% for TN. For each stage, NS decreased with increasing grade. Comparing periods of diagnosis (2004-2009 vs 2010-2014), 10-NS remained &amp;gt;90% for women with stage I BC, but improved for stage III and aggressive subtypes (HR\u2212\/HER2+ and TN). In women with stage III HR\u2212\/HER2+ BC, 10-NS increased from 48.6% to 87.9% (+39 percentage points), while when diagnosis was stage III TN BC it rose from 28.8% to 42.3%<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Population-based estimates of long-term BC survival by combined stage, grade, and molecular subtype can inform the interpretation of evolving therapeutic strategies and improve risk stratification for patient follow-up.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag338","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:20:46Z","timestamp":1787570446000},"source":"Crossref","is-referenced-by-count":0,"title":["Ten-year survival of women with invasive breast cancer by stage, molecular subtype, and grade combined: a population-based study"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4160-3479","authenticated-orcid":false,"given":"Fabiola","family":"Giudici","sequence":"first","affiliation":[{"name":"Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-8920","authenticated-orcid":false,"given":"Diego","family":"Serraino","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS , Aviano, 33081,","place":["Italy"]},{"name":"Department of Medicine, University of Udine , Udine, 33100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4717-0544","authenticated-orcid":false,"given":"Samuele","family":"Massarut","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-4834","authenticated-orcid":false,"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS , Aviano, 33081,","place":["Italy"]},{"name":"Department of Medicine, University of Udine , Udine, 33100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7687-2276","authenticated-orcid":false,"given":"Serena","family":"Scomersi","sequence":"additional","affiliation":[{"name":"Breast Surgery Unit, Cattinara University Hospital , Trieste, 34149,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2907-0745","authenticated-orcid":false,"given":"Federica","family":"Toffolutti","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8273-9084","authenticated-orcid":false,"given":"Ettore","family":"Bidoli","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6163-200X","authenticated-orcid":false,"given":"Luigino","family":"Dal Maso","sequence":"additional","affiliation":[{"name":"Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Friuli Venezia Giulia Cancer Registry working group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Angelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia De","family":"Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ornella","family":"Forgiarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Lazzaretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariella","family":"Losciale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Taborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"2026092210522697300_oyag338-B1","first-page":"e70090","article-title":"Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries","volume":"76","author":"Sung","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"2026092210522697300_oyag338-B2","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B3","doi-asserted-by":"publisher","author":"OECD, European Commission","year":"2025","DOI":"10.1787\/20ef03e1-en"},{"key":"2026092210522697300_oyag338-B4","author":"AIOM","year":"2024"},{"key":"2026092210522697300_oyag338-B5","doi-asserted-by":"crossref","first-page":"103635","DOI":"10.1016\/j.esmoop.2024.103635","article-title":"Patients with cancer who will be cured and projections of complete prevalence in Italy from 2018 to 2030","volume":"9","author":"Guzzinati","year":"2024","journal-title":"ESMO Open"},{"key":"2026092210522697300_oyag338-B6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(23)00646-0","article-title":"Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study","volume":"25","author":"De Angelis","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026092210522697300_oyag338-B7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"2026092210522697300_oyag338-B8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2016.206","article-title":"The combined endocrine receptor in breast cancer, a novel approach to traditional hormone receptor interpretation and a better discriminator of outcome than ER and PR alone","volume":"115","author":"Campbell","year":"2016","journal-title":"Br J Cancer"},{"key":"2026092210522697300_oyag338-B9","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO\u2013college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026092210522697300_oyag338-B10","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.2147\/CMAR.S176763","article-title":"Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study","volume":"10","author":"Xiao","year":"2018","journal-title":"Cancer Manag Res"},{"key":"2026092210522697300_oyag338-B11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ijc.31914","article-title":"Ten-year recurrence rates for breast cancer subtypes in The Netherlands: a large population-based study","volume":"144","author":"Van Maaren","year":"2019","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10585-015-9697-2","article-title":"Pattern of metastasis and outcome in patients with breast cancer","volume":"32","author":"Gerratana","year":"2015","journal-title":"Clin Exp Metastasis"},{"key":"2026092210522697300_oyag338-B13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1634\/theoncologist.2014-0002","article-title":"Measures of outcome in metastatic breast cancer: insights from a real-world scenario","volume":"19","author":"Bonotto","year":"2014","journal-title":"Oncologist"},{"key":"2026092210522697300_oyag338-B14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13058-025-02012-x","article-title":"Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland","volume":"27","author":"Mesa-Eguiagaray","year":"2025","journal-title":"Breast Cancer Res"},{"key":"2026092210522697300_oyag338-B15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/ijc.34923","article-title":"Cure indicators and prevalence by stage at diagnosis for breast and colorectal cancer patients: a population-based study in Italy","volume":"155","author":"Dal Maso","year":"2024","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B16","doi-asserted-by":"crossref","first-page":"h4901","DOI":"10.1136\/bmj.h4901","article-title":"Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients","volume":"351","author":"Saadatmand","year":"2015","journal-title":"BMJ"},{"key":"2026092210522697300_oyag338-B17","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"key":"2026092210522697300_oyag338-B18","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.5858\/arpa.2013-0435-OA","article-title":"Histologic grade remains a prognostic factor for breast cancer regardless of the number of positive lymph nodes and tumor size: a study of 161 708 cases of breast cancer from the SEER program","volume":"138","author":"Schwartz","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"2026092210522697300_oyag338-B19","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"key":"2026092210522697300_oyag338-B20","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"2026092210522697300_oyag338-B21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejca.2017.07.015","article-title":"Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: a EUROCARE-5 study","volume":"84","author":"Minicozzi","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026092210522697300_oyag338-B22","author":"Bosetti","year":"2025"},{"key":"2026092210522697300_oyag338-B23","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/ijc.35516","article-title":"Future of population-based cancer registries: a global perspective\u2014a survey of population-based cancer registries","volume":"157","author":"Van Eycken","year":"2025","journal-title":"Intl J Cancer"},{"key":"2026092210522697300_oyag338-B24","first-page":"353","article-title":"Aggiornamento della sopravvivenza dei pazienti con tumore in italia: confronti geografici e focus su pazienti con tumori oggetto di screening, pediatrici e associati al fumo","volume":"46","author":"Ravaioli","year":"2022","journal-title":"E&P"},{"key":"2026092210522697300_oyag338-B25","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"2026092210522697300_oyag338-B26","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999\u20132007: results of the EUROCARE-5 study","volume":"51","author":"Sant","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026092210522697300_oyag338-B27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026092210522697300_oyag338-B28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13058-021-01393-z","article-title":"In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study","volume":"23","author":"Johansson","year":"2021","journal-title":"Breast Cancer Res"},{"key":"2026092210522697300_oyag338-B29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/030089161209800611","article-title":"Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on italian women","volume":"98","author":"Cortesi","year":"2012","journal-title":"Tumori"},{"key":"2026092210522697300_oyag338-B30","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1007\/s00432-022-04245-1","article-title":"10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis","volume":"149","author":"Intrieri","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026092210522697300_oyag338-B31","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/ijc.33417","article-title":"Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in The Netherlands between 1989 and 2017","volume":"148","author":"Van Der Meer","year":"2021","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B32","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/0284186X.2018.1532601","article-title":"Breast cancer survival trends in different stages and age groups\u2013a population-based study 1989\u20132013","volume":"58","author":"Nordenskj\u00f6ld","year":"2019","journal-title":"Acta Oncol"},{"key":"2026092210522697300_oyag338-B33","volume-title":"International Statistical Classification of Diseases and Related Health Problems","author":"World Health Organization","edition":"5th rev. ed"},{"key":"2026092210522697300_oyag338-B34","first-page":"1","volume-title":"Standards and Guidelines for Cancer Registration in Europe","author":"Weltgesundheitsorganisation, International Agency for Research on Cancer","year":"2003"},{"key":"2026092210522697300_oyag338-B35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Perme","year":"2012","journal-title":"Biometrics"},{"key":"2026092210522697300_oyag338-B36","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1186\/s12885-016-2967-9","article-title":"Analysing population-based cancer survival\u2013settling the controversies","volume":"16","author":"Pohar Perme","year":"2016","journal-title":"BMC Cancer"},{"key":"2026092210522697300_oyag338-B37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1002\/ijc.27830","article-title":"Cancer net survival on registry data: Use of the new unbiased pohar-perme estimator and magnitude of the bias with the classical methods","volume":"132","author":"Roche","year":"2013","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B38","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/cancers14143304","article-title":"Net survival in survival analyses for patients with cancer: a scoping review","volume":"14","author":"Nagamine","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026092210522697300_oyag338-B39","author":"Istituto Nazionale di Statistica (ISTAT)","year":"2025"},{"key":"2026092210522697300_oyag338-B40","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2025"},{"key":"2026092210522697300_oyag338-B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v087.i08","article-title":"Nonparametric relative survival analysis with the R package relsurv","volume":"87","author":"Perme","year":"2018","journal-title":"J Stat Soft"},{"key":"2026092210522697300_oyag338-B42","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1002\/ijc.34863","article-title":"Age-related phenotypes in breast cancer: a population-based study","volume":"154","author":"Svan\u00f8e","year":"2024","journal-title":"Intl Journal of Cancer"},{"key":"2026092210522697300_oyag338-B43","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ijc.31950","article-title":"Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort","volume":"144","author":"Johansson","year":"2019","journal-title":"Int J Cancer"},{"key":"2026092210522697300_oyag338-B44","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.breast.2023.02.004","article-title":"Early breast cancer in women aged 35 years or younger: a large national multicenter French population-based case control-matched analysis","volume":"68","author":"Dufour","year":"2023","journal-title":"Breast"},{"key":"2026092210522697300_oyag338-B45","doi-asserted-by":"crossref","first-page":"e35729","DOI":"10.1002\/cncr.35729","article-title":"Outcomes and treatment patterns for stage I human epidermal growth factor receptor 2-positive breast cancer in the surveillance, epidemiology, and end results database, 2010\u20132019","volume":"131","author":"Waks","year":"2025","journal-title":"Cancer"},{"key":"2026092210522697300_oyag338-B46","doi-asserted-by":"crossref","first-page":"103862","DOI":"10.1016\/j.breast.2024.103862","article-title":"Survival feature and trend of female breast cancer: a comprehensive review of survival analysis from cancer registration data","volume":"79","author":"Tang","year":"2025","journal-title":"Breast"},{"key":"2026092210522697300_oyag338-B47","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO-24-01507","article-title":"Development and validation of the RSClinN\u2009+\u2009tool to predict prognosis and chemotherapy benefit for hormone receptor\u2013positive, node-positive breast cancer","volume":"43","author":"Pusztai","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092210522697300_oyag338-B48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41523-021-00286-w","article-title":"Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer","volume":"7","author":"Puglisi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2026092210522697300_oyag338-B49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4048\/jbc.2018.21.e53","article-title":"Clinical differences in Triple-Positive operable breast cancer subtypes in Korean patients: an analysis of Korean breast cancer registry data","volume":"21","author":"You","year":"2018","journal-title":"J Breast Cancer"},{"key":"2026092210522697300_oyag338-B50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10549-007-9556-1","article-title":"An overview of prognostic factors for long-term survivors of breast cancer","volume":"107","author":"Soerjomataram","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2026092210522697300_oyag338-B51","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1186\/s12885-018-4666-1","article-title":"The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review","volume":"18","author":"Broeders","year":"2018","journal-title":"BMC Cancer"},{"key":"2026092210522697300_oyag338-B52","first-page":"145","article-title":"Early effects of attendance to the friuli venezia giulia (Northern Italy) mammography screening programme on the incidence of advanced-stage breast cancer: a cohort study","volume":"44","author":"Giudici","year":"2020","journal-title":"E&P"},{"key":"2026092210522697300_oyag338-B53","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"2026092210522697300_oyag338-B54","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of breast cancer mortality in the US\u20141975 to 2019","volume":"331","author":"Caswell-Jin","year":"2024","journal-title":"JAMA"},{"key":"2026092210522697300_oyag338-B55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10549-024-07469-6","article-title":"Trends in HR\u2009+ metastatic breast cancer survival before and after CDK4\/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2\u2212 and HER2+ metastatic breast cancer","volume":"208","author":"Brufsky","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"2026092210522697300_oyag338-B56","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/jnci\/djae241","article-title":"Trends in breast cancer\u2013specific death by clinical stage at diagnoses between 2000 and 2017","volume":"117","author":"Marczyk","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"2026092210522697300_oyag338-B57","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.canep.2015.04.001","article-title":"Cause-specific or relative survival setting to estimate population-based net survival from cancer? An empirical evaluation using women diagnosed with breast cancer in Geneva between 1981 and 1991 and followed for 20 years after diagnosis","volume":"39","author":"Schaffar","year":"2015","journal-title":"Cancer Epidemiol"},{"key":"2026092210522697300_oyag338-B58","doi-asserted-by":"crossref","first-page":"104487","DOI":"10.1016\/j.breast.2025.104487","article-title":"A population-based estimation of breast cancer recurrence in northeast Italy with administrative healthcare databases","volume":"82","author":"Giudici","year":"2025","journal-title":"Breast"},{"key":"2026092210522697300_oyag338-B59","doi-asserted-by":"crossref","first-page":"e2400249","DOI":"10.1200\/GO-24-00249","article-title":"Collecting long-term outcomes in population-based cancer registry data: the case of breast cancer recurrence","volume":"10","author":"Morgan","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"2026092210522697300_oyag338-B60","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ejca.2016.12.030","article-title":"Advanced breast cancer rates in the epoch of service screening: the 400,000 women cohort study from Italy","volume":"75","author":"Puliti","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026092210522697300_oyag338-B61","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1200\/JCO.2015.65.8013","article-title":"Subtype-dependent relationship between young age at diagnosis and breast cancer survival","volume":"34","author":"Partridge","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026092210522697300_oyag338-B62","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3389\/fonc.2020.01729","article-title":"The prognostic impact of age at diagnosis upon breast cancer of different immunohistochemical subtypes: a surveillance, epidemiology, and end results (SEER) Population-Based analysis","volume":"10","author":"Cai","year":"2020","journal-title":"Front Oncol"},{"key":"2026092210522697300_oyag338-B63","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1016\/j.ejca.2004.07.022","article-title":"Hybrid analysis for up-to-date long-term survival rates in cancer registries with delayed recording of incident cases","volume":"40","author":"Brenner","year":"2004","journal-title":"Eur J Cancer"},{"key":"2026092210522697300_oyag338-B64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/(SICI)1097-0258(19990228)18:4<441::AID-SIM23>3.0.CO;2-M","article-title":"Mixture models for cancer survival analysis: application to population-based data with covariates","volume":"18","author":"De Angelis","year":"1999","journal-title":"Statist Med"},{"key":"2026092210522697300_oyag338-B65","author":"Presidente Del Consiglio Dei Ministri","year":"2017"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag338\/70784370\/oyag338.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag338\/70784370\/oyag338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag338\/70784370\/oyag338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:52:42Z","timestamp":1790088762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag338\/8770366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag338","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,25]]},"article-number":"oyag338"}}